SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $477,432 | -28.1% | 32,881 | +3.7% | 0.00% | -25.0% |
| Q2 2023 | $663,732 | +8.2% | 31,712 | +9.2% | 0.00% | 0.0% |
| Q1 2023 | $613,304 | -4.2% | 29,039 | +15.4% | 0.00% | 0.0% |
| Q4 2022 | $640,526 | +5.5% | 25,168 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $607,000 | +30.3% | 25,261 | +4.3% | 0.00% | +33.3% |
| Q2 2022 | $466,000 | +9.9% | 24,221 | -0.6% | 0.00% | +50.0% |
| Q1 2022 | $424,000 | -18.9% | 24,369 | +2.0% | 0.00% | -33.3% |
| Q4 2021 | $523,000 | +11.3% | 23,896 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $470,000 | +8.5% | 24,610 | -2.3% | 0.00% | +200.0% |
| Q2 2021 | $433,000 | +6.9% | 25,196 | +39.0% | 0.00% | 0.0% |
| Q1 2021 | $405,000 | +16.4% | 18,126 | +15.8% | 0.00% | 0.0% |
| Q4 2020 | $348,000 | +46.2% | 15,658 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $238,000 | -2.5% | 16,107 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $244,000 | +68.3% | 16,474 | +24.3% | 0.00% | 0.0% |
| Q1 2020 | $145,000 | +30.6% | 13,253 | +5.3% | 0.00% | – |
| Q4 2019 | $111,000 | +16.8% | 12,587 | -0.8% | 0.00% | – |
| Q3 2019 | $95,000 | -20.2% | 12,694 | -0.7% | 0.00% | – |
| Q2 2019 | $119,000 | +138.0% | 12,782 | +34.5% | 0.00% | – |
| Q1 2019 | $50,000 | +22.0% | 9,503 | +3.0% | 0.00% | – |
| Q4 2018 | $41,000 | -45.3% | 9,226 | -0.8% | 0.00% | – |
| Q3 2018 | $75,000 | +10.3% | 9,297 | -3.7% | 0.00% | – |
| Q2 2018 | $68,000 | -36.4% | 9,658 | +28.3% | 0.00% | – |
| Q1 2018 | $107,000 | +55.1% | 7,527 | -5.1% | 0.00% | – |
| Q4 2017 | $69,000 | 0.0% | 7,931 | +34.2% | 0.00% | – |
| Q3 2017 | $69,000 | -9.2% | 5,908 | +8.1% | 0.00% | – |
| Q2 2017 | $76,000 | +90.0% | 5,467 | +88.4% | 0.00% | – |
| Q1 2017 | $40,000 | +110.5% | 2,902 | +7.1% | 0.00% | – |
| Q4 2016 | $19,000 | -100.0% | 2,710 | -0.3% | 0.00% | – |
| Q3 2016 | $41,205,000 | +54.1% | 2,718 | +0.1% | 0.00% | – |
| Q2 2016 | $26,733,000 | – | 2,714 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |